Eli Lilly extends partnership with Insilico Medicine for AI drug discovery
Pharmaceutical company Eli Lilly has expanded its existing partnership with AI company Insilico Medicine to use artificial intelligence for drug discovery efforts. The deal extends their previous collaboration focused on applying AI technology to pharmaceutical research and development.
8
Divergence score
2 outlets covered it, splitting into 2 framing camps across 2 bias groups.
2 camps
2 bias groups
The spectrum · how 2 outlets placed this story
LeftCenterRight
Wall Street Journal
Reuters
Supportive of action
Neutral
Dismissive
Critical
Alarmist
International angle
Widest split · the two outlets furthest apart, and who published first
First to report
- Reutersfirst
- Wall Street Journal+2.1 h
By each outlet's earliest publish time in this story. Feeds that index slowly can appear later than they printed.
How each outlet covered it
Lightly covered so far
Too few outlets to map a left-right split. Here is each take as it stands.
Sparse coverage · 2 outlets
“Eli Lilly extends partnership with Insilico Medicine for AI-powered drug discovery - Reuters”
“Eli Lilly, InSilico Strike AI Drug Discovery Deal - WSJ”
5 tracked claims across 2 outlets
Fact ledger
All5Claimed4Corroborated1
1/2
Claimed
The deal is an extension of an existing partnership between the two companies.
Corroborated
Disputed
4 more tracked claimsSign up free to see the full ledger